Preventive effect of a synbiotic combination of galacto- and fructooligosaccharides mixture with Bifidobacterium breve M-16V in a model of multiple rotavirus infections

Frontiers in Immunology

Volumn 9, Issue JUN, 2018, Pages

  Rigo Adrover, Maria del Mar ^a   van Limpt, Kees ^b   Knipping, Karen ^b,c   Garssen, Johan ^b,c   Knol, Jan ^b   Costabile, Adele ^d   Franch, Àngels ^a   Castell, Margarida ^a   Pérez Cano, Francisco José ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b DANONE NUTRICIA RESEARCH   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF ROEHAMPTON   (United Kingdom)

Author keywords

Bifidobacterium breve; FOS; GOS; Prebiotic; Probiotic; Rotavirus; Synbiotic

Indexed keywords

CLAUDIN 2; FRUCTOSE OLIGOSACCHARIDE; GALACTOSE OLIGOSACCHARIDE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; M 16V; OCCLUDIN; PROBIOTIC AGENT; SHORT CHAIN FATTY ACID; SYNBIOTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEAD IMMUNOASSAY; BIFIDOBACTERIUM BREVE; BLOOD; BODY TEMPERATURE MEASUREMENT; BODY WEIGHT; BOVINE; CELL MATURATION; COLOSTRUM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DIET SUPPLEMENTATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FECES; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOASSAY; LIMIT OF QUANTITATION; NEWBORN; NONHUMAN; PH MEASUREMENT; PROPHYLAXIS; RAT; RAT MODEL; REAL TIME POLYMERASE CHAIN REACTION; ROTAVIRUS INFECTION; SPLEEN; VIRUS SHEDDING;

EID: 85048290137     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.01318     Document Type: Article

References (75)

1. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis (2003) 9(5):565-72. doi:10.3201/eid0905.020562
2. Parashar UD, Johnson H, Steele AD, Tate JE. Health impact of rotavirus vaccination in developing countries: progress and way forward. Clin Infect Dis (2016) 62(Suppl 2):S91-5. doi:10.1093/cid/civ1015
3. Tate JE, Burton AH, Boschi-Pinto C, Parashar UD. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000-2013. Clin Infect Dis (2016) 62(Suppl 2):S96-105. doi:10.1093/cid/civ1013
4. Greenberg HB, Estes MK. Rotaviruses: from pathogenesis to vaccination. Gastroenterology (2009) 136(6):1939-51. doi:10.1053/j.gastro.2009.02.076
5. Román Riechmann Enriqueta. In: Undergraf SL, editor. Infección por rotavirus. Madrid: Enriqueta Román Riechmann (2006). p. 67-75
6. Clarke E, Desselberger U. Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings. Mucosal Immunol (2015) 8(1):1-17. doi:10.1038/mi.2014.114
7. Gray J. Rotavirus vaccines: safety, efficacy and public health impact. J Intern Med (2011) 270(3):206-14. doi:10.1111/j.1365-2796.2011.02409.x
8. Chen S-C, Tan L-B, Huang L-M, Chen K-T. Rotavirus infection and the current status of rotavirus vaccines. J Formos Med Assoc (2012) 111(4):183-93. doi:10.1016/j.jfma.2011.09.024
9. Hu L, Crawford SE, Hyser JM, Estes MK, Prasad BV. Rotavirus non-structural proteins: structure and function. Curr Opin Virol (2012) 2(4):380-8. doi:10.1016/j.coviro.2012.06.003
10. Sánchez-San Martín C, López T, Arias CF, López S. Characterization of rotavirus cell entry. J Virol (2004) 78(5):2310-8. doi:10.1128/JVI.78.5.2310-2318.2004
11. Gonzalez-Ochoa G, Flores-Mendoza LK, Icedo-Garcia R, Gomez-Flores R, Tamez-Guerra P. Modulation of rotavirus severe gastroenteritis by the combination of probiotics and prebiotics. Arch Microbiol (2017) 199(7):953-61. doi:10.1007/s00203-017-1400-3
12. Jiang B, Gentsch JR, Glass RI. The role of serum antibodies in the protection against rotavirus disease: an overview. Clin Infect Dis (2002) 34(10):1351-61. doi:10.1086/340103
13. Lopez-Guerrero DV, Meza-Perez S, Ramirez-Pliego O, Santana-Calderon MA, Espino-Solis P, Gutierrez-Xicotencatl L, et al. Rotavirus infection activates dendritic cells from Peyer's patches in adult mice. J Virol (2010) 84(4):1856-66. doi:10.1128/JVI.02640-08
14. Moon S, Wang Y, Dennehy P, Simonsen KA, Zhang J, Jiang B. Antigenemia, RNAemia, and innate immunity in children with acute rotavirus diarrhea. FEMS Immunol Med Microbiol (2012) 64(3):382-91. doi:10.1111/j.1574-695X.2011.00923.x
15. Franco MA, Greenberg HB. Immunity to rotavirus infection in mice. J Infect Dis (1999) 179(Suppl 3):S466-9. doi:10.1086/314805
16. Azevedo MSP, Yuan L, Iosef C, Chang K-O, Kim Y, Van Nguyen T, et al. Magnitude of serum and intestinal antibody responses induced by sequential replicating and nonreplicating rotavirus vaccines in gnotobiotic pigs and correlation with protection. Clin Diagn Lab Immunol (2004) 11(1):12-20. doi:10.1128/CDLI.11.1.12-20.2004
17. Blutt SE, Miller AD, Salmon SL, Metzger DW, Conner ME. IgA is important for clearance and critical for protection from rotavirus infection. Mucosal Immunol (2012) 5(6):712-9. doi:10.1038/mi.2012.51
18. O'Neal WK, Zhou H, Morral N, Langston C, Parks RJ, Graham FL, et al. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Mol Med (2000) 6(3):179-95
19. Churgay CA, Aftab Z. Gastroenteritis in children: part II. Prevention and management. Am Fam Physician (2012) 85(11):1066-70
20. Bines JE, Kirkwood CD. Conquering rotavirus: from discovery to global vaccine implementation. J Paediatr Child Health (2015) 51(1):34-9. doi:10.1111/jpc.12815
21. World Health Organization (WHO). [Internet]. Rotavirus Vaccines WHO Position Paper (2013) [cited 2016 Jul 22]. Available from: http://www.who.int/immunization/policy/position_papers/rotavirus/en/
22. Wolber FM, Broomfield AM, Fray L, Cross ML, Dey D. Supplemental dietary whey protein concentrate reduces rotavirus-induced disease symptoms in suckling mice. J Nutr (2005) 135(6):1470-4. doi:10.1093/jn/135.6.1470
23. Pérez-Cano FJ, Marín-Gallén S, Castell M, Rodríguez-Palmero M, Rivero M, Castellote C, et al. Supplementing suckling rats with whey protein concentrate modulates the immune response and ameliorates rat rotavirus-induced diarrhea. J Nutr (2008) 138(12):2392-8. doi:10.3945/jn.108.093856
24. Inagaki M, Yamamoto M, Uchida K, Yamaguchi H, Kawasaki M, Yamashita K, et al. In vitro and in vivo evaluation of the efficacy of bovine colostrum against human rotavirus infection. Biosci Biotechnol Biochem (2010) 74(3):680-2. doi:10.1271/bbb.90862
25. Parreño V, Marcoppido G, Vega C, Garaicoechea L, Rodriguez D, Saif L, et al. Milk supplemented with immune colostrum: protection against rotavirus diarrhea and modulatory effect on the systemic and mucosal antibody responses in calves experimentally challenged with bovine rotavirus. Vet Immunol Immunopathol (2010) 136(1-2):12-27. doi:10.1016/j.vetimm.2010.01.003
26. Knipping K, McNeal MM, Crienen A, van Amerongen G, Garssen J, Van't Land B. A gastrointestinal rotavirus infection mouse model for immune modulation studies. Virol J (2011) 8(1):109. doi:10.1186/1743-422X-8-109
27. Inagaki M, Yamamoto M, Cairangzhuoma, Xijier, Yabe T, Uchida K, et al. Multiple-dose therapy with bovine colostrum confers significant protection against diarrhea in a mouse model of human rotavirus-induced gastrointestinal disease. J Dairy Sci (2013) 96(2):806-14. doi:10.3168/jds.2012-5847
28. Rigo-Adrover M, Franch A, Castell M, Castellote C, Pérez-Cano FJ. Whey protein is beneficial for rotavirus-induced diarrhoea in preclinical studies. In: Preedy VR, Watson RR, Zibadi S, editors. Handbook of Dietary and Nutritional Aspects of Bottle Feeding. The Netherlands: Wageningen Academic Publishers (2014). p. 491-506
29. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol (2014) 11:506-14. doi:10.1038/nrgastro.2014.66
30. Buccigrossi V, Laudiero G, Russo C, Miele E, Sofia M, Monini M, et al. Chloride secretion induced by rotavirus is oxidative stress-dependent and inhibited by Saccharomyces boulardii in human enterocytes. PLoS One (2014) 9(6):e99830. doi:10.1371/journal.pone.0099830
31. Maragkoudakis PA, Chingwaru W, Gradisnik L, Tsakalidou E, Cencic A. Lactic acid bacteria efficiently protect human and animal intestinal epithelial and immune cells from enteric virus infection. Int J Food Microbiol (2010) 141(Suppl 1):91-7. doi:10.1016/j.ijfoodmicro.2009.12.024
32. Varyukhina S, Freitas M, Bardin S, Robillard E, Tavan E, Sapin C, et al. Glycan-modifying bacteria-derived soluble factors from Bacteroides thetaiotaomicron and Lactobacillus casei inhibit rotavirus infection in human intestinal cells. Microbes Infect (2012) 14(3):273-8. doi:10.1016/j.micinf.2011.10.007
33. Liu F, Li G, Wen K, Bui T, Cao D, Zhang Y, et al. Porcine small intestinal epithelial cell line (IPEC-J2) of rotavirus infection as a new model for the study of innate immune responses to rotaviruses and probiotics. Viral Immunol (2010) 23(2):135-49. doi:10.1089/vim.2009.0088
34. Duffy LC, Zielezny MA, Riepenhoff-Talty M, Dryja D, Sayahtaheri-Altaie S, Griffiths E, et al. Effectiveness of Bifidobacterium bifidum in mediating the clinical course of murine rotavirus diarrhea. Pediatr Res (1994) 35(6):690-5. doi:10.1203/00006450-199406000-00014
35. Guérin-Danan C, Meslin JC, Chambard A, Charpilienne A, Relano P, Bouley C, et al. Food supplementation with milk fermented by Lactobacillus casei DN-114 001 protects suckling rats from rotavirus-associated diarrhea. J Nutr (2001) 131(1):111-7. doi:10.1093/jn/131.1.111
36. Grandy G, Medina M, Soria R, Terán CG, Araya M. Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children. BMC Infect Dis (2010) 10:253. doi:10.1186/1471-2334-10-253
37. Szymanski H, Pejcz J, Jawien M, Chmielarczyk A, Strus M, Heczko PB. Treatment of acute infectious diarrhoea in infants and children with a mixture of three Lactobacillus rhamnosus strains-a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther (2006) 23(2):247-53. doi:10.1111/j.1365-2036.2006.02740.x
38. Erdogan ö, Tanyeri B, Torun E, Gönüllü E, Arslan H, Erenberk U, et al. The comparison of the efficacy of two different probiotics in rotavirus gastroenteritis in children. J Trop Med (2012) 2012:787240. doi:10.1155/2012/787240
39. Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics (1991) 88(1):90-7
40. Suárez JE. Autochthonous microbiota, probiotics and prebiotics. Nutr Hosp (2015) 31(Suppl 1):3-9. doi:10.3305/nh.2015.31.sup1.8701
41. Corzo N, Alonso JL, Azpiroz F, Calvo MA, Cirici M, Leis R, et al. Prebiotics: concept, properties and beneficial effects. Nutr Hosp (2015) 31(Suppl 1):99-118. doi:10.3305/nh.2015.31.sup1.8715
42. Li M, Monaco MH, Wang M, Comstock SS, Kuhlenschmidt TB, Fahey GC Jr, et al. Human milk oligosaccharides shorten rotavirus-induced diarrhea and modulate piglet mucosal immunity and colonic microbiota. ISME J (2014) 8:1609-20. doi:10.1038/ismej.2014.10
43. Rigo-Adrover M, Saldaña-Ruíz S, van Limpt K, Knipping K, Garssen J, Knol J, et al. A combination of scGOS/lcFOS with Bifidobacterium breve M-16V protects suckling rats from rotavirus gastroenteritis. Eur J Nutr (2017) 56(4):1657-70. doi:10.1007/s00394-016-1213-1
44. Noguera T, Wotring R, Melville CR, Hargraves K, Kumm J, Morton JM, et al. Resolution of acute gastroenteritis symptoms in children and adults treated with a novel polyphenol-based prebiotic. World J Gastroenterol (2014) 20(34):12301-7. doi:10.3748/wjg.v20.i34.12301
45. Binns CW, Lee AH, Harding H, Gracey M, Barclay DV. The CUPDAY Study: prebiotic-probiotic milk product in 1-3-year-old children attending childcare centres. Acta Paediatr Int J Paediatr (2007) 96(11):1646-50. doi:10.1111/j.1651-2227.2007.00508.x
46. Reeves PG, Nielsen FH, Fahey GC. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr (1993) 123(11):1939-51. doi:10.1093/jn/123.11.1939
47. Pérez-Cano FJ, Castell M, Castellote C, Franch A. Characterization of clinical and immune response in a rotavirus diarrhea model in suckling Lewis rats. Pediatr Res (2007) 62(6):658-63. doi:10.1203/PDR.0b013e318159a273
48. Pérez-Cano FJ, Marín-Gallén S, Castell M, Rodríguez-Palmero M, Rivero M, Franch A, et al. Bovine whey protein concentrate supplementation modulates maturation of immune system in suckling rats. Br J Nutr (2007) 98(Suppl 1):S80-4. doi:10.1017/S0007114507838074
49. Andreas NJ, Kampmann B, Mehring Le-Doare K. Human breast milk: a review on its composition and bioactivity. Early Hum Dev (2015) 91(11):629-35. doi:10.1016/j.earlhumdev.2015.08.013
50. Pérez-Cano FJ, Castellote C, González-Castro AM, Pelegrí C, Castell M, Franch A. Developmental changes in intraepithelial T lymphocytes and NK cells in the small intestine of neonatal rats. Pediatr Res (2005) 58(5):885-91. doi:10.1203/01.pdr.0000182187.88505.49
51. Ramos-Romero S, Pérez-Cano FJ, Castellote C, Castell M, Franch A. Effect of cocoa-enriched diets on lymphocytes involved in adjuvant arthritis in rats. Br J Nutr (2012) 107(3):378-87. doi:10.1017/S0007114511003035
52. Pérez-Cano FJ, Castellote C, Marín-Gallén S, Franch A, Castell M. Neonatal immunoglobulin secretion and lymphocyte phenotype in rat small intestine lamina propria. Pediatr Res (2005) 58(1):164-9. doi:10.1203/01.PDR.0000156367.60769.36
53. Abril-Gil M, Massot-Cladera M, Pérez-Cano FJ, Castellote C, Franch à, Castell M. A diet enriched with cocoa prevents IgE synthesis in a rat allergy model. Pharmacol Res (2012) 65(6):603-8. doi:10.1016/j.phrs.2012.02.001
54. Perez-Cano FJ, Ramirez-Santana C, Molero-Luis M, Castell M, Rivero M, Castellote C, et al. Mucosal IgA increase in rats by continuous CLA feeding during suckling and early infancy. J Lipid Res (2009) 50(3):467-76. doi:10.1194/jlr. M800356-JLR200
55. Hattori K, Yamamoto A, Sasai M, Taniuchi S, Kojima T, Kobayashi Y, et al. Effects of administration of bifidobacteria on fecal microflora and clinical symptoms in infants with atopic dermatitis. Aerugi (2003) 52(1):20-30
56. Schouten B, van Esch BCAM, Hofman GA, van Doorn SACM, Knol J, Nauta AJ, et al. Cow milk allergy symptoms are reduced in mice fed dietary synbiotics during oral sensitization with whey. J Nutr (2009) 139(7):1398-403. doi:10.3945/jn.109.108514
57. Izumi H, Minegishi M, Sato Y, Shimizu T, Sekine K, Takase M. Bifidobacterium breve alters immune function and ameliorates DSS-induced inflammation in weanling rats. Pediatr Res (2015) 78(4):407-16. doi:10.1038/pr.2015.115
58. Salvatore S, Vandenplas Y. Prebiotics and probiotics in therapy and prevention of gastrointestinal diseases in children. In: Watson RR, Preedy VR, editors. Bioactive Foods in Promoting Health. London: Elsevier (2010). p. 181-203
59. Veereman-Wauters G, Staelens S, Van de Broek H, Plaskie K, Wesling F, Roger LC, et al. Physiological and bifidogenic effects of prebiotic supplements in infant formulae. J Pediatr Gastroenterol Nutr (2011) 52(6):763-71. doi:10.1097/MPG.0b013e3182139f39
60. Guérin-Danan C, Meslin JC, Lambre F, Charpilienne A, Serezat M, Bouley C, et al. Development of a heterologous model in germfree suckling rats for studies of rotavirus diarrhea. J Virol (1998) 72(11):9298-302
61. Ciarlet M, Conner ME, Finegold MJ, Estes MK. Group A rotavirus infection and age-dependent diarrheal disease in rats: a new animal model to study the pathophysiology of rotavirus infection. J Virol (2002) 76(1):41-57. doi:10.1128/JVI.76.1.41-57.2002
62. Liu F, Wen K, Li G, Yang X, Kocher J, Bui T, et al. Dual functions of Lactobacillus acidophilus NCFM as protection against rotavirus diarrhea. J Pediatr Gastroenterol Nutr (2014) 58(2):169-76. doi:10.1097/MPG.0000000000000197
63. Sindhu KNC, Sowmyanarayanan TV, Paul A, Babji S, Ajjampur SSR, Priyadarshini S, et al. Immune response and intestinal permeability in children with acute gastroenteritis treated with Lactobacillus rhamnosus GG: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis (2014) 58(8):1107-15. doi:10.1093/cid/ciu065
64. Wen K, Liu F, Li G, Bai M, Kocher J, Yang X, et al. Lactobacillus rhamnosus GG dosage affects the adjuvanticity and protection against rotavirus diarrhea in gnotobiotic pigs. J Pediatr Gastroenterol Nutr (2015) 60(6):834-43. doi:10.1097/MPG.0000000000000694
65. Rigo-Adrover MD, Franch à, Castell M, Pérez-Cano FJ. Preclinical immunomodulation by the probiotic Bifidobacterium breve M-16V in early life. PLoS One (2016) 11(11):e0166082. doi:10.1371/journal.pone.0166082
66. Sheridan JF, Eydelloth RS, Vonderfecht SL, Aurelian L. Virus-specific immunity in neonatal and adult-mouse rotavirus infection. Infect Immun (1983) 39(2):917-27
67. Gandhi GR, Santos VS, Denadai M, da Silva Calisto VK, de Souza Siqueira Quintans J, de Oliveira e Silva AM, et al. Cytokines in the management of rotavirus infection: a systematic review of in vivo studies. Cytokine (2017) 96:152-60. doi:10.1016/j.cyto.2017.04.013
68. Hardy H, Harris J, Lyon E, Beal J, Foey AD. Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. Nutrients (2013) 5(6):1869-912. doi:10.3390/nu5061869
69. Wen K, Tin C, Wang H, Yang X, Li G, Giri-Rachman E, et al. Probiotic Lactobacillus rhamnosus GG enhanced Th1 cellular immunity but did not affect antibody responses in a human gut microbiota transplanted neonatal gnotobiotic pig model. PLoS One (2014) 9(4):e94504. doi:10.1371/journal.pone.0094504
70. Howarth GS, Wang H. Role of endogenous microbiota, probiotics and their biological products in human health. Nutrients (2013) 5(1):58-81. doi:10.3390/nu5010058
71. Wang H, Gao K, Wen K, Allen IC, Li G, Zhang W, et al. Lactobacillus rhamnosus GG modulates innate signaling pathway and cytokine responses to rotavirus vaccine in intestinal mononuclear cells of gnotobiotic pigs transplanted with human gut microbiota. BMC Microbiol (2016) 16(1):109. doi:10.1186/s12866-016-0727-2
72. Djouzi Z, Andrieux C. Compared effects of three oligosaccharides on metabolism of intestinal microflora in rats inoculated with a human faecal flora. Br J Nutr (1997) 78(2):313-24. doi:10.1079/BJN19970149
73. Pan X, Chen F, Wu T, Tang H, Zhao Z. Prebiotic oligosaccharides change the concentrations of short-chain fatty acids and the microbial population of mouse bowel. J Zhejiang Univ Sci B (2009) 10(4):258-63. doi:10.1631/jzus. B0820261
74. Grimaldi R, Swann JR, Vulevic J, Gibson GR, Costabile A. Fermentation properties and potential prebiotic activity of B-GOS (65% GOS content) on in vitro gut microbiota parameters. Br J Nutr (2016) 116(3):480-6. doi:10.1017/S0007114516002269
75. Macfarlane GT, Macfarlane S. Fermentation in the human large intestine: its physiologic consequences and the potential contribution of prebiotics. J Clin Gastroenterol (2011) 45l(3):S120-7. doi:10.1097/MCG.0b013e31822fecfe